FiberNEW2026

Butyrate Regulating Inflammatory Responses in Chronic Obstructive Pulmonary Disease via the Gut-Lung Axis.

Liu Qiang, Fu Qian, Sun Caiyuan, Liu Chanli et al. — International journal of chronic obstructive pulmonary disease

Summary

Eating fiber-rich foods helps your gut bacteria produce a substance called butyrate. This review suggests that butyrate might play a role in reducing lung inflammation for some people with Chronic Obstructive Pulmonary Disease (COPD) by influencing the communication pathway between the gut and lungs. This highlights a potential link between diet, gut health, and respiratory conditions.

AI-generated summary — read the original

Key points

Dietary fiber supports gut bacteria that produce beneficial compounds like butyrate.
Butyrate may help reduce lung inflammation in certain types of Chronic Obstructive Pulmonary Disease (COPD).
This effect is thought to occur through a connection between the gut and the lungs, known as the gut-lung axis.
More research is needed to confirm these benefits and translate them into clinical practice for human patients.

What the study looked at

This review explored how butyrate, a short-chain fatty acid produced by gut bacteria from dietary fiber, might influence inflammatory responses in Chronic Obstructive Pulmonary Disease (COPD) through the 'gut-lung axis.' This was a narrative review, meaning the authors synthesized existing preclinical evidence (from lab and animal studies) and limited clinical evidence from human studies. It did not involve new experiments or direct participation from individuals. The review suggests that butyrate could help reduce inflammation in COPD by strengthening the gut's protective barrier and balancing immune responses. However, its anti-inflammatory effects appeared more validated in a specific subtype of COPD (type 2 inflammatory, affecting 20-40% of patients), with less robust evidence for the more common type. The authors also highlighted challenges for clinical use, such as how the body processes butyrate and the need for more human trials.

Dietary takeaway

While this research is still in its early stages and one review is not definitive, it highlights the potential importance of a fiber-rich diet for overall health, including respiratory well-being. Consuming a variety of fruits, vegetables, whole grains, and legumes can support a healthy gut microbiome, which produces beneficial compounds like butyrate. This ongoing area of research suggests that what we eat can influence our health in surprising ways, but more studies are needed before specific dietary recommendations can be made for conditions like COPD.

Abstract

Chronic obstructive pulmonary disease (COPD) poses a major global health challenge, yet current pulmonary-directed therapies offer only symptomatic relief without modifying the underlying systemic inflammatory pathology. The gut-lung axis has emerged as a pivotal cross-organ regulatory circuit in COPD progression, and butyrate-a key microbial short-chain fatty acid derived from dietary fibre fermentation-mediates pleiotropic immunomodulatory effects that bridge intestinal homeostasis and pulmonary inflammation. This narrative review synthesises preclinical and limited clinical evidence to elucidate the regulatory functions of butyrate in COPD inflammation via the gut-lung axis, organising its core mechanisms into four major modules: strengthening intestinal mucosal barrier integrity, suppressing type 2 innate lymphoid cell overactivation, restoring the Th17/Treg homeostatic balance, and interrupting pathological endothelial-macrophage inflammatory crosstalk. Importantly, the therapeutic potential of butyrate is phenotype-restricted; its anti-inflammatory actions are primarily validated in the type 2 inflammatory COPD subtype, which affects only 20-40% of patients, whereas robust evidence for efficacy in the predominant neutrophilic phenotype remains scarce. Translational hurdles further impede clinical application, including poor oral bioavailability due to first-pass hepatic metabolism, insufficient human clinical verification, and the theoretical risk of excessive immunosuppression at elevated concentrations. Moreover, most mechanistic inferences are drawn from in vitro studies and cigarette smoke-induced animal models that incompletely recapitulate the heterogeneous pathophysiology of human COPD. This review critically appraises the current theoretical framework of butyrate-mediated gut-lung co-regulation, delineates the applicable patient subsets and core limitations of butyrate intervention, and highlights priority research directions encompassing phenotype-stratified clinical trials, optimised targeted delivery systems, and comparative analyses of multiple short-chain fatty acids. Although butyrate offers a promising theoretical foundation for developing novel gut-lung coordinated disease-modifying strategies, rigorous stratified clinical validation remains essential to ascertain its genuine therapeutic value in practice.

View on PubMed →DOI: 10.2147/COPD.S621848